Table 2.
Linear array (LA) signal strength among HPV positive men in the Rakai circumcision trial
| Trial Arm | Frequency LA band intensity of 4/total* (%) |
Prevalence ratio of ‘4’ band intensity comparing intervention to control arm |
95% CI |
|---|---|---|---|
| (A) LA band intensities for all positive infections detected by LA for 37 HPV genotypes at baseline and 24 months | |||
| Baseline | |||
| Control | 126/628 (20.1%) | ||
| Intervention | 181/691 (26.2%) | 1.31 | (1.07 to 1.59) |
| 24 months | |||
| Control | 124/394 (31.4%) | ||
| Intervention | 32/166 (19.2%) | 0.61 | (0.43 to 0.86) |
| (B) LA intensities limited to HPV 16, 18, 31, 33, 35 and 52 | |||
| Baseline | |||
| Control | 22/111 (19.8%) | ||
| Intervention | 34/134 (24.3%) | 1.28 | (0.80 to 2.06) |
| 24 months | |||
| Control | 23/78 (29.4%) | ||
| Intervention | 4/25 (16.0%) | 0.54 | (0.21 to 1.42) |
| (C) LA positive results limited to infections that were detectable at 1 visit only (no persistent infections) | |||
| Baseline | |||
| Control | 99/547 (18.1%) | ||
| Intervention | 168/662 (25.3%) | 1.4 | (1.13 to 1.75) |
| 24 months | |||
| Control | 98/321 (30.5%) | ||
| Intervention | 26/137 (18.9%) | 0.62 | (0.42 to 0.91) |
*
Frequency of LA band intensities of ‘4’ on a scale of 1–4 among HPV positives. Data are presented as number of ‘4’ intensities/total number of HPV-positive infections, and percentage of ‘4’ intensities.